Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

BackgroundThe calreticulin (CALR) exon 9 mutations that are identified in 20% of patients with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) generate immunogenic antigens. Thus, therapeutic cancer vaccination against mutant CALR could be a new treatment modality in CALR...

Full description

Bibliographic Details
Main Authors: Jacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Jørgensen, Uffe Klausen, Stine Emilie Weis-Banke, Daniel El Fassi, Claudia Schöllkopf, Mette Borg Clausen, Lise Mette Rahbek Gjerdrum, Marie Fredslund Breinholt, Julie Westerlin Kjeldsen, Morten Hansen, Steffen Koschmieder, Nicolas Chatain, Guy Wayne Novotny, Jesper Petersen, Lasse Kjær, Vibe Skov, Özcan Met, Inge Marie Svane, Hans Carl Hasselbalch, Mads Hald Andersen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
myeloproliferative neoplasms
cancer immune therapy
cancer vaccines
neo-antigen
calreticulin
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.637420/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.637420/full

Similar Items